Burning Rock Biotech (NASDAQ:BNR) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Burning Rock Biotech (NASDAQ:BNR) from a hold rating to a buy rating in a research note issued to investors on Sunday morning.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Burning Rock Biotech in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.

Burning Rock Biotech Trading Down 6.9%

BNR stock opened at $21.77 on Friday. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.14 and a quick ratio of 2.91. The company has a market capitalization of $234.25 million, a PE ratio of -13.11 and a beta of 1.20. The firm’s 50-day moving average is $15.26 and its 200 day moving average is $9.70. Burning Rock Biotech has a 12 month low of $2.18 and a 12 month high of $24.18.

Institutional Investors Weigh In On Burning Rock Biotech

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. purchased a new stake in Burning Rock Biotech during the third quarter worth about $26,000. Prospera Financial Services Inc acquired a new stake in shares of Burning Rock Biotech during the 3rd quarter valued at approximately $214,000. Finally, Crcm LP boosted its stake in shares of Burning Rock Biotech by 13.8% during the 3rd quarter. Crcm LP now owns 221,575 shares of the company’s stock worth $1,917,000 after acquiring an additional 26,809 shares in the last quarter. Hedge funds and other institutional investors own 30.03% of the company’s stock.

About Burning Rock Biotech

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.